

****Updated November 2014****

MarketVIEW: Tuberculosis vaccines

Product Name	:	MarketVIEW: Tuberculosis vaccines
Description	:	Vaccine commercial opportunity analysis
Contents	:	Executive presentation + forecast model
Therapeutic Area	:	Endemic/developing world vaccines
Publication date	:	November 2014
Catalogue No	:	VAMV021

Background

Mycobacterium tuberculosis (M.tb) currently infects around one-third of the world's population. Although the majority of infections are latent and asymptomatic, between 5-10% of individuals develop active disease, which is both contagious and able to cause severe morbidity and death. Most of M.tb infections occur in sub-Saharan Africa where co-infection with HIV is a significant contributor to disease burden.

The BCG vaccine has been widely adopted by greater than 100 countries with high coverage to protect against systemic TB in children. However, the vaccine does not prevent or eliminate Mtb infection, especially later in life. In many countries with high and rising TB incidence rates – BCG has failed to control the epidemic. Vaccine manufacturers and academic groups are currently investigating new TB vaccines which could either replace BCG or boost its effect. The most advanced candidates in development are Oxford University (OU/Aeras) MVA85A and M72 + AS01E (GSK Biologicals).

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a novel TB vaccines (all mechanisms of action) across global markets to 2035. The model contains value (\$ m) and volume (mio doses) predictions for high and low TB burden countries in the infants (<1yrs), children, adolescents and adult target groups. Differing TB vaccine profiles and related issues such as differential pricing are also discussed.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to tuberculosis vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of endemic vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Published November 2014 (CAT No: VAMV021)

****This product is composed of a summary presentation

Author's note

Contents

Executive Summary

Key commercial model outputs

TB vaccines (all types) combined sales (\$m), 2015-35 [Hi case]

TB vaccines: available market per vaccine type (\$m) to 2035 [Hi case]

TB volume (vaccinees), by target population, 2015-35 [Hi case]

TB vaccines: available market per competitor (\$m) to 2035 [Base case]

TB vaccine sales (\$m), by country (base case), 2030

TB vaccine sales (\$m), by target population and country, 2030

TB vaccines: commercial model assumptions

The role of new TB vaccines

New TB vaccines: mechanisms overview

Pre-exposure (prime) vaccines - infants

Pre-exposure (prime-boost) vaccines - infants/adolescents

Post-exposure (prime-boost) vaccines - adults

Therapeutic vaccines

Populations/vaccines modelled

Market categorization

Country model inputs: vaccine adoption, coverage and pricing

Detailed country assumptions

TB disease trends and dynamics

TB incidence rates by country, 2013

Estimated number of incident TB cases (all forms), 2013

Global disability-adjusted life years (DALYs) per 100,000 population, 2012

BCG vaccination: overview

BCG vaccination policy by country

TB vaccine pipeline overview

Comment on TB vaccine candidates

MVA85A (AERAS-485)

Ad35/MVA85A combination

M72 (GSK Biologicals)

H4 (AERAS-404)

H56 (AERAS-456)

ID93

Continued....

VPM1002
MTBVAC
Ad5Ag85A
Whole-cell or fragmented mycobacteria vaccines
Launch timings
Bibliography
About **VacZine Analytics**

PAGES: 52 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – MS Excel forecast presentation

Title sheet
Chart summary
Value summary by country (2030)
Market share/competitors
Value summary
Vaccinees summary
Country models =>
China
India
Indonesia
Bangladesh
Pakistan
Philippines
Brazil
Russia
South Korea
South Africa
Other (UMI or HI)
Other (LI or LMI)
Other LATAM
Sub-Saharan Africa
Pricing
Country-based data
Forecast TB incidence
GAVI countries
BCG vaccine schedule
Births
12 yrs
13 to 15 yrs
Adults
Clinical trials
Charts
Income group
Backpage

37 worksheets - interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8995.00**/ GBP **£5620.00**[#] (Region license)*
- PRESENTATION OR FORECAST MODEL ONLY – USD **\$4995.00**/ GBP **£2500.00**[#] (Region license)*

[#] Indicative rate only. Prevailing rate applied to date of transaction.

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. WHO. Global tuberculosis report 2014. Available at: http://www.who.int/tb/publications/global_report/en/. Accessed: published November 2014
 2. WHO. Tuberculosis data. Available at: <http://www.who.int/tb/country/data/download/en/>. Accessed: published November 2014
 3. WHO. Global Health Observatory (GHO). DALYs by region, 2012. Available at: http://www.who.int/gho/mortality_burden_disease/daly_rates/en/. Accessed: published November 2014.
 4. Trunz BB et al. Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. *Lancet*. 2006 Apr 8;367(9517):1173-80.
 5. Hesseling AC et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. *Vaccine*. 2007 Jan 2;25(1):14-8.
 6. Zwerling A et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. *PLoS Med*. 2011 Mar;8(3):e1001012.
 7. Aeras. Global Pipeline of TB Vaccine Candidates. Available at: <http://www.aeras.org/pages/portfolio-approach>. Accessed: published November 2014.
 8. Aeras. Clinical Portfolio. Available at: <http://www.aeras.org/candidates>. Accessed: published November 2014
 9. Tameris MD et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *Lancet*. 2013 Mar 23;381(9871):1021-8.
 10. WHO Questions and Answers on Tuberculosis Vaccines. 4 February 2013. Available at: <http://www.who.int/tb/vaccinesfaqs/en/>. Accessed: published November 2014
 11. Montagnani C et al. Vaccine against tuberculosis: what's new? *BMC Infect Dis*. 2014;14 Suppl 1:S2.
 12. Prevention of infection study underway in South Africa. Available at: <http://www.aeras.org/pressreleases/>. Accessed: published November 2014.
 13. TB vaccine report. Available at: <http://www.pipelinerreport.org/2014/tb-vaccine>. Accessed: published November 2014
 14. Frick. M. The Tuberculosis Vaccines Pipeline. June 2013. Available at: <http://www.pipelinerreport.org/2013/tb-vaccine>. Accessed: published November 2014.
- Weiner J 3rd et al. Recent advances towards tuberculosis control: vaccines and biomarkers. *J Intern Med*. 2014 May;275(5):467-80

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
Spain
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the Spain. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009

Follow us on Twitter **@vaczineanalytic**

Signup to our newsletter ExpertREACT - <http://www.vaczine-analytics.com/products-expertreact.asp>